Weekly γ-hydroxybutyrate exposure sensitizes locomotor hyperactivity to low-dose 3,4-methylenedioxymethamphetamine in rats

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 195-203

  Van Nieuwenhuijzen, P S ^a   Li, K M ^b   Hunt, G E ^a   McGregor, I S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

Author keywords

Hydroxybutyrate; 3,4 Methylenedioxymethamphetamine; 5 Hydroxytryptamine; Dopamine; Polydrug use; Sensitization

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; DOPAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EXPOSURE; ENVIRONMENTAL TEMPERATURE; GENETICALLY HYPERTENSIVE RAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; HYPERTHERMIA; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DRUG INTERACTIONS; HALLUCINOGENS; LOCOMOTION; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SEROTONIN; SODIUM OXYBATE; TEMPERATURE;

EID: 70449482729     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253555     Document Type: Article

References (56)

1. Baylen CA, Rosenberg H: A review of the acute subjective effects of MDMA/ecstasy. Addiction 2006; 101: 933-947
2. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508
3. El-Mallakh RS, Abraham HD: MDMA (Ecstasy). Ann Clin Psychiatry 2007; 19: 45-52
4. Morley KC, McGregor IS: (+/-)-3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. Eur J Pharmacol 2000; 408: 41-49
5. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS: A role for oxytocin and 5-HT 1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ('ecstasy'). Neuroscience 2007; 146: 509-514
6. Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI: Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures. Br J Pharmacol 2005; 146: 306-312
7. Banks ML, Sprague JE, Kisor DF, Czoty PW, Nichols DE, Nader MA: Ambient temperature effects on 3,4-methylenedioxymethamphetamine- induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab Dispos 2007; 35: 1840-1845
8. Baumann MH, Wang X, Rothman RB: 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: A reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189: 407-424
9. Gouzoulis-Mayfrank E, Daumann J: The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. J Psychopharmacol 2006; 20: 188-193
10. Uys JD, Niesink RJ: Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and- - hydroxybutyric acid (GHB): A review of the literature. Drug Alcohol Rev 2005; 24: 359-368
11. Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM: Use, function, and subjective experiences of- -hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92: 286-290
12. Degenhardt L, Dunn M: The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy 2008; 19: 311-316
13. Mason PE, Kerns WP 2nd:- -Hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9: 730-739
14. Lingenhoehl K, Brom R, Heid J, Beck P, Froestl W, Kaupmann K, Bettler B, Mosbacher J:- -Hydroxybutyrate is a weak agonist at recombinant GABA B receptors. Neuropharmacology 1999; 38: 1667-1673
15. Gobaille S, Schleef C, Hechler V, Viry S, Aunis D, Maitre M:- -Hydroxybutyrate increases tryptophan availability and potentiates serotonin turnover in rat brain. Life Sci 2002; 70: 2101-2112
16. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Luscher C: Bi-directional effects of GABA B receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004; 7: 153-159
17. Colombo G, Agabio R, Balaklievskaia N, Diaz G, Lobina C, Reali R, Gessa GL: Oral self-administration of- -hydroxybutyric acid in the rat. Eur J Pharmacol 1995; 285: 103-107
18. Martellotta MC, Fattore L, Cossu G, Fratta W: Rewarding properties of- -hydroxybutyric acid: An evaluation through place preference paradigm. Psychopharmacology (Berl) 1997; 132: 1-5
19. Cousins MS, Roberts DC, de Wit H: GABA B receptor agonists for the treatment of drug addiction: A review of recent findings. Drug Alcohol Depend 2002; 65: 209-220
20. Stewart J, Badiani A: Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 1993; 4: 289-312
21. Robinson TE, Berridge KC: The psychology and neurobiology of addiction: An incentivesensitization view. Addiction 2000; 95(suppl 2):S91-S117
22. Robinson TE, Berridge KC: The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-291
23. Crombag HS, Badiani A, Chan J, Dell'Orco J, Dineen SP, Robinson TE: The ability of environmental context to facilitate psychomotor sensitization to amphetamine can be dissociated from its effect on acute drug responsiveness and on conditioned responding. Neuropsychopharmacology 2001; 24: 680-690
24. Ball KT, Budreau D, Rebec GV: Context-dependent behavioural and neuronal sensitization in striatum to MDMA (ecstasy) administration in rats. Eur J Neurosci 2006; 24: 217-228
25. Modi GM, Yang PB, Swann AC, Dafny N: Chronic exposure to MDMA (Ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants. Behav Brain Funct 2006; 2: 1
26. Ramos M, Goni-Allo B, Aguirre N: Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: An effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade. Neuropsychopharmacology 2005; 30: 2180-2191
27. Clemens KJ, Cornish JL, Hunt GE, Mc- Gregor IS: Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 2007; 86: 183-190
28. Brennan KA, Schenk S: Initial deficit and recovery of function after MDMA pre-exposure in rats. Psychopharmacology (Berl) 2006; 184: 239-246
29. Parrott AC: Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005; 19: 71-83
30. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB: Dancing hot on Ecstasy: Physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Hum Psychopharmacol 2006; 21: 285-298
31. Boot BP, McGregor IS, Hall W: MDMA (Ecstasy) neurotoxicity: Assessing and communicating the risks. Lancet 2000; 355: 1818- 1821
32. Van Nieuwenhuijzen PS, McGregor IS, Hunt GE:- -Hydroxybutyrate (GHB) induced Fos expression: Comparison with baclofen. Neuroscience 2009;158:441-455
33. Spanos LJ, Yamamoto BK: Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 1989; 32: 835-840
34. Hall DA, Stanis JJ, Marquez Avila H, Gulley JM: A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: Evidence for qualitative differences in behavior. Psychopharmacology (Berl) 2008; 195: 469-478
35. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE: Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 2003; 168: 465-474
36. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS: MDMA ('ecstasy'), methamphetamine and their combination: Long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 2004; 173: 318-325
37. Aberg M, Wade D, Wall E, Izenwasser S: Effect of MDMA (ecstasy) on activity and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol Teratol 2007; 29: 37-46
38. Bartoletti M, Gubellini C, Ricci F, Gaiardi M: Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine. Behav Pharmacol 2005; 16: 553-558.
39. Steketee JD, Beyer CE: Injections of baclofen into the ventral medial prefrontal cortex block the initiation, but not the expression, of cocaine sensitization in rats. Psychopharmacology (Berl) 2005; 180: 352-358
40. Bartoletti M, Gubellini C, Ricci F, Gaiardi M: The GABAB agonist baclofen blocks the expression of sensitisation to the locomotor stimulant effect of amphetamine. Behav Pharmacol 2004; 15: 397-401
41. Queva C, Bremner-Danielsen M, Edlund A, Ekstrand AJ, Elg S, Erickson S, Johansson T, Lehmann A, Mattsson JP: Effects of GABA agonists on body temperature regulation in GABA B 1 -/- mice. Br J Pharmacol 2003; 140: 315-322
42. Koek W, France CP: Cataleptic effects of- - hydroxybutyrate (GHB) and baclofen in mice: Mediation by GABA B receptors, but differential enhancement by N-methyl- D - aspartate (NMDA) receptor antagonists. Psychopharmacology (Berl) 2008;199:191-198
43. Vanderschuren LJ, Kalivas PW: Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology (Berl) 2000; 151: 99-120
44. Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, Minardi G, Gessa GL: Role of GABA B receptors in the sedative/ hypnotic effect of- -hydroxybutyric acid. Eur J Pharmacol 2001; 428: 315-321
45. Smith MA, Gergans SR, Lyle MA: The motor-impairing effects of GABAA and GABA B agonists in- -hydroxybutyrate (GHB)-treated rats: Cross-tolerance to baclofen but not flunitrazepam. Eur J Pharmacol 2006; 552: 83-89
46. Mechan AO, O'Shea E, Elliott JM, Cola - do MI, Green AR: A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a longterm defect in thermoregulation. Psychopharmacology (Berl) 2001; 155: 413-418
47. Patel MM, Belson MG, Longwater AB, Olson KR, Miller MA: Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 2005; 29: 451-454
48. Snead OC, 3rd:- -Hydroxybutyric-acid-induced seizures bear no relation to core temperature. Epilepsia 1990; 31: 253-258
49. Green AR, O'Shea E, Colado MI: A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004; 500: 3-13
50. Hechler V, Peter P, Gobaille S, Bourguignon JJ, Schmitt M, Ehrhardt JD, Mark J, Maitre M:- -Hydroxybutyrate ligands possess antidopaminergic and neuroleptic-like activities. J Pharmacol Exp Ther 1993; 264: 1406-1414
51. Maitre M: The- -hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-361
52. Gold LH, Koob GF: MDMA produces stimulant- like conditioned locomotor activity. Psychopharmacology (Berl) 1989; 99: 352-356
53. Modi GM, Yang PB, Swann AC, Dafny N: Chronic exposure to MDMA (Ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants. Behav Brain Funct 2006; 2: 1-12
54. O'Shea E, Granados R, Esteban B, Colado MI, Green AR: The relationship between the degree of neurodegeneration of rat brain 5- HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998; 37: 919-926
55. Kalivas PW, Duffy P, White SR: MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 1998; 18: 469-479
56. Ramos M, Goni-Allo B, Aguirre N: Ibotenic acid lesions of the medial prefrontal cortex block the development and expression of 3,4- methylenedioxymethamphetamine-induced behavioral sensitization in rats. Behav Brain Res 2005; 160: 304-311